Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SYNAGIS vs ARZERRA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Palivizumab is a humanized monoclonal antibody that binds to the A antigenic site of the fusion (F) protein of respiratory syncytial virus (RSV), inhibiting viral entry into host cells by preventing fusion of the viral envelope with the host cell membrane.
Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 molecule on B lymphocytes, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20+ cells.
Prophylaxis of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients with bronchopulmonary dysplasia (BPD), history of preterm birth (≤35 weeks gestational age), or hemodynamically significant congenital heart disease (CHD)
Treatment of chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab,Treatment of previously untreated CLL in combination with chlorambucil,Treatment of relapsed CLL in combination with fludarabine and cyclophosphamide
15 mg/kg intramuscular once monthly during RSV season. Maximum dose: 300 mg (2 m L) per injection.
ARZERRA (ofatumumab) for chronic lymphocytic leukemia (CLL): Initial dose 300 mg IV, then 1 week later 2000 mg IV weekly for 6 doses, then 2000 mg IV every 4 weeks for up to 4 additional doses. For relapsed CLL: 300 mg IV followed by 1000 mg IV on day 8, then 1000 mg IV on day 15 and day 22 of cycle 1, then 1000 mg IV on day 1 of cycles 2-6 (28-day cycles). Premedicate with acetaminophen, antihistamine, and corticosteroid.
18-27 days (terminal half-life in pediatric patients, mean ~21 days). Allows monthly dosing during RSV season.
Mean terminal elimination half-life after first dose is approximately 14 days (range 7–21 days) and increases with repeated dosing due to target-mediated clearance saturation; at steady state, half-life is ~24 days.
Palivizumab is a monoclonal antibody; it is degraded into small peptides and amino acids via catabolic pathways, similar to endogenous Ig G. No specific metabolic enzymes are involved.
Ofatumumab is a monoclonal antibody; metabolism is not through typical cytochrome P450 pathways. Clearance involves catabolism to peptides and amino acids.
Renal: minimal intact Ig G recovered in urine; likely catabolized to peptides/amino acids. Fecal/biliary: not significantly eliminated. Main route: proteolytic catabolism.
Arzerra (ofatumumab) is eliminated primarily via the reticuloendothelial system and catabolism; renal excretion is minimal (<1% of dose as intact antibody). Biliary/fecal excretion has not been characterized, but as a monoclonal antibody, it is not significantly excreted in urine or feces.
~98-99% bound, primarily to Ig G receptors (Fc Rn) and endogenous Ig G; binding to other serum proteins minimal.
As a monoclonal antibody, ofatumumab does not bind to plasma proteins; protein binding is negligible.
~1.0-1.5 L/kg in infants; reflects distribution primarily within vascular space and extracellular fluid.
Volume of distribution (Vd) is approximately 2.5–4.5 L, approximating plasma volume; does not distribute extensively into tissues (not reported in L/kg, but typical for Ig G1 monoclonal antibodies ~0.1–0.2 L/kg).
IM: ~80-100% (nearly complete absorption after intramuscular injection).
Subcutaneous: ~60–70% absolute bioavailability; intravenous: 100%.
No dose adjustment required for renal impairment.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or hemodialysis; use with caution.
No dose adjustment required for hepatic impairment.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe hepatic impairment (Child-Pugh B or C); use with caution.
Infants and children up to 24 months: 15 mg/kg intramuscular once monthly during RSV season. Maximum dose: 300 mg per injection.
Safety and efficacy in pediatric patients (<18 years) have not been established; no recommended dosing.
Not indicated for use in adults; no geriatric dosing data available.
No specific dose adjustment required for elderly patients. Clinical studies included patients ≥65 years; overall efficacy and safety similar to younger adults, but higher incidence of serious infections and cardiac events observed.
None
Hepatitis B virus (HBV) reactivation can occur with ofatumumab, leading to fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before initiation. Monitor HBV carriers during and after treatment.
Anaphylaxis and hypersensitivity reactions (rare but severe),Coagulation disorders (thrombocytopenia) with bleeding complications in patients with CHD,Risk of infection transmission if administered with contaminated equipment,Not indicated for treatment of RSV disease,May interfere with RSV diagnostic tests
Infusion reactions (including anaphylaxis), prolonged cytopenias, progressive multifocal leukoencephalopathy (PML), intestinal obstruction, tumor lysis syndrome, and infections including hepatitis B reactivation.
History of severe hypersensitivity reaction to palivizumab or any component of the product
Known hypersensitivity (anaphylaxis) to ofatumumab or any of its excipients.
No known food interactions. Administer without regard to meals.
No known food interactions. Take with or without food.
Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Palivizumab is a humanized monoclonal antibody (Ig G1) that crosses the placenta, with increasing transfer in the second and third trimesters. No teratogenic effects have been reported. Use only if clearly needed.
ARZERRA (ofatumumab) is a human monoclonal antibody. Ig G molecules cross the placenta increasingly after the first trimester. Based on its mechanism of action (B-cell depletion), there is a potential risk of fetal B-cell lymphocytopenia and impaired immune response. Data from animal studies are insufficient. The drug should be avoided during pregnancy unless the benefit clearly outweighs the risk.
Not known whether palivizumab is excreted in human milk. Ig G antibodies are transferred into milk, but systemic absorption by the infant is minimal. M/P ratio not established. Consider developmental benefits of breastfeeding versus theoretical risk of exposure. Caution advised.
It is unknown whether ofatumumab is excreted in human milk. Human Ig G is present in breast milk, but levels are low. Due to the potential for serious adverse reactions in the breastfed infant (including B-cell depletion), breastfeeding is not recommended during therapy and for at least 6 months after the last dose. No M/P ratio is available.
No dosing adjustments required due to pregnancy. Pharmacokinetics of palivizumab are not expected to be significantly altered by pregnancy. Standard dosing: 15 mg/kg intramuscularly once monthly during RSV season.
No specific dose adjustment guidelines are established for pregnancy. The pharmacokinetics of monoclonal antibodies may be altered due to increased plasma volume and clearance in pregnancy, but no formal studies have been conducted. Use caution and consider therapeutic drug monitoring if available.
Administer intramuscularly only, preferably in the anterolateral thigh; do not use if turbid or discolored; observe for 30 minutes post-injection for hypersensitivity; not for treatment of RSV disease; efficacy unproven in children with congenital heart disease other than hemodynamically significant conditions; may interfere with immune response to live vaccines; palivizumab is a monoclonal antibody, not a vaccine.
ARZERRA (ofatumumab) is a monoclonal antibody targeting CD20 used in relapsing multiple sclerosis. First dose reactions are common; premedicate with corticosteroids, antihistamines, and antipyretics. Monitor for infections, especially hepatitis B reactivation. Contraindicated in active hepatitis B. Administer as subcutaneous injection; injection site reactions frequent. Live vaccines contraindicated during and after treatment until immune reconstitution.
This medication is given as a shot to prevent serious RSV lung infection; it does not treat existing infection.,Your child will receive injections monthly during RSV season (typically November through March).,Common side effects include fever, rash, and injection site reactions like redness or swelling.,Seek medical attention if your child develops signs of allergic reaction: hives, difficulty breathing, swelling of face/lips.,Inform healthcare provider about any bleeding disorders or recent vaccinations before receiving Synagis.
Report any signs of infection (fever, chills, cough, painful urination) promptly.,Inform your doctor of any history of hepatitis B infection.,You will receive premedication before the first dose to reduce allergic reactions.,Do not receive live vaccines during treatment or until your doctor confirms immune recovery.,Common side effects include injection site reactions, headache, and fever.,ARZERRA is given as an injection under the skin; rotation of injection sites is recommended.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SYNAGIS vs ARZERRA, answered by our medical review team.
SYNAGIS is a Monoclonal Antibody that works by Palivizumab is a humanized monoclonal antibody that binds to the A antigenic site of the fusion (F) protein of respiratory syncytial virus (RSV), inhibiting viral entry into host cells by preventing fusion of the viral envelope with the host cell membrane.. ARZERRA is a Antineoplastic, Monoclonal Antibody that works by Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 molecule on B lymphocytes, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20+ cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SYNAGIS and ARZERRA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SYNAGIS is: 15 mg/kg intramuscular once monthly during RSV season. Maximum dose: 300 mg (2 m L) per injection.. The standard adult dose of ARZERRA is: ARZERRA (ofatumumab) for chronic lymphocytic leukemia (CLL): Initial dose 300 mg IV, then 1 week later 2000 mg IV weekly for 6 doses, then 2000 mg IV every 4 weeks for up to 4 additional doses. For relapsed CLL: 300 mg IV followed by 1000 mg IV on day 8, then 1000 mg IV on day 15 and day 22 of cycle 1, then 1000 mg IV on day 1 of cycles 2-6 (28-day cycles). Premedicate with acetaminophen, antihistamine, and corticosteroid.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SYNAGIS and ARZERRA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SYNAGIS is classified as Category C. Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Palivizumab is a humanized monoclonal antibody (IgG1) that c. ARZERRA is classified as Category C. ARZERRA (ofatumumab) is a human monoclonal antibody. IgG molecules cross the placenta increasingly after the first trimester. Based on its mechanism of action (B-cell depletion), t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.